Breast Cancer: A21102 (Hematology Oncology Associates)

A21102 Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias

Objective

The purpose of this study is to compare the effects, good and/or bad, of testosterone, with a placebo (an inactive agent) on joint pain caused by taking aromatase inhibitors.

Eligible patients for this study are those that have been diagnosed with breast cancer, and are receiving a treatment with an aromatase inhibitor, either anastrozole or letrozole, and are experiencing joint symptoms. It is well known that treatment with an aromatase inhibitor (AI) can cause side effects that result in symptoms such as joint pain and stiffness, which can interfere with activities of daily living. In some patients, the treatment has to be stopped because of these symptoms. 






 



Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Breast Cancer
Sponsor(s)
Alliance for Clinical Trials in Oncology
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email